Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.08
Nov 16 • 3:59 PM ET Dollar change-0.05 Percentage change(-4.42%)
Aftermarket Close
1.10
Aftermarket • 7:30 PM ET Dollar change+0.02 Percentage change(1.85%)
Nov 16, 8:07 AMBioVie reports Phase 2 ADDRESS-LC data showing bezisterim associated with 33% lower neuropeptide Y; NIH adds biomarker to RECOVER prioritization list
Index
-
Market Cap
11.58M
Enterprise Value
4.10M
Income
-22.59M
Sales
0.00M
Book/sh
0.75
Cash/sh
0.72
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
May 05, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.44
P/C
1.50
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.40
Current Ratio
2.40
Debt/Eq
0.04
LT Debt/Eq
0.02
Option/Short
No / Yes
EPS (ttm)
-2.89
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
72.98% 70.98%
Sales past 3/5Y
- -
EPS Y/Y TTM
67.39%
Sales Y/Y TTM
-
EPS Q/Q
31.12%
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
0.00% -
Insider Own
3.63%
Insider Trans
7.09%
Inst Own
20.05%
Inst Trans
5.05%
ROA
-119.34%
ROE
-143.66%
ROIC
-337.80%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-17.78%
SMA50
-26.05%
SMA200
-29.04%
Trades
Shs Outstand
10.72M
Shs Float
10.34M
52W High
3.79 -71.50%
52W Low
0.82 31.71%
Volatility
8.02% 14.56%
ATR (14)
0.18
RSI (14)
39.04
Beta
0.81
Rel Volume
0.06
Avg Volume
2.49M
Volume
160,211
Perf Week
-16.92%
Perf Month
-10.00%
Perf Quarter
11.99%
Perf Half Y
-20.59%
Perf YTD
-6.90%
Perf Year
-28.00%
Perf 3Y
-99.72%
Perf 5Y
-99.82%
Perf 10Y
-99.97%
Prev Close
1.13
Price
1.08
Change %
-4.42%
Consensus
Strong Buy
Avg. Price Target
$5.00
Implied Upside
+363.0%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 22, 2022Initiated
CCantor Fitzgerald
Overweight$7+548.1%
Jan 15, 2021Initiated
RILY logoRB. Riley Securities
Buy$47+4,251.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DO CUONG VPresident & CEONov 13 '26Buy1.162,5002,90618,617Nov 16 04:30 PM
Palumbo Joseph MChief Medical OfficerAug 28 '26Buy2.164,84310,4616,036Aug 28 09:01 PM
Chappell Amy SuzonDirectorAug 28 '26Buy2.167271,570727Aug 28 09:01 PM
KIM JOANNE WENDYChief Financial OfficerAug 28 '26Buy2.182,5005,4503,441Aug 28 08:58 PM
DO CUONG VPresident & CEOAug 27 '26Buy2.0815,21031,63716,117Aug 28 08:57 PM
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.
PresidentMr. Cuong Viet Do M.B.A.
CFOMs. Joanne Wendy Kim CPA
Executive VP of R&D and Chief Medical OfficerDr. Joseph M. Palumbo M.D.
Senior Vice President of OperationsMr. Clarence N. Ahlem
Senior Vice President of Liver Disease & Long COVID ProgramsDr. Penelope Markham Ph.D.